Spots Global Cancer Trial Database for neoplasms, germ cell and embryonal
Every month we try and update this database with for neoplasms, germ cell and embryonal cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT04222972 | RET-fusion Non ... Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Disea... Head and Neck N... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Germ... Neoplasms, Nerv... | Pralsetinib Carboplatin Cisplatin Pemetrexed Pembrolizumab Gemcitabine Paclitaxel Nab-Paclitaxel | 18 Years - | Hoffmann-La Roche | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients | NCT00393861 | Neoplasms, Germ... | Bevacizumab and... | 18 Years - | Indiana University | |
| Vorasidenib Expanded Access Program | NCT05592743 | Glioma Recurrence Disease Attribu... Pathologic Proc... Neoplasms, Neur... Neuroectodermal... Neoplasms, Germ... Neoplasms by Hi... Neoplasms Neoplasms, Glan... Neoplasms, Nerv... | Vorasidenib | 12 Years - | Servier | |
| Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin | NCT00611962 | Neoplasms, Germ... | Oxaliplatin, Pa... | 18 Years - | Sanofi | |
| Multicenter Database of Patients With Germ Cell Tumor | NCT02863003 | Neoplasms, Germ... | 18 Years - | Latin American Cooperative Oncology Group | ||
| Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy | NCT02839694 | Neoplasm Metast... Sarcoma Neoplasms, Germ... Melanoma | decitabine (DAC... Tetrahydrouridi... Celecoxib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors | NCT02197169 | Glioblastoma or... | Single intratum... Interferon-gamm... | 18 Years - | DNAtrix, Inc. | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors | NCT01177007 | Liver Neoplasms | TheraSphere, Yt... | 18 Years - | Yale University | |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | NCT03037385 | RET-altered Non... Medullary Thyro... RET-altered Pap... RET-altered Col... RET-altered Sol... Lung Neoplasm Carcinoma, Non-... Thyroid Disease... Thyroid Neoplas... Thyroid Cancer,... Carcinoma, Neur... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Endocrine Syste... Endocrine Gland... Head and Neck N... Adenocarcinoma,... Adenocarcinoma Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neuroendocrine ... Neuroectodermal... Neoplasms, Germ... Neoplasms, Nerv... Colonic Neoplas... Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... | pralsetinib (BL... | 18 Years - | Hoffmann-La Roche | |
| Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients | NCT04657315 | Glioblastoma Adult Gliosarco... Neoplasms, Brai... Neoplasms, Germ... Recurrent Gliob... | MSC11FCD | 19 Years - 70 Years | CHA University | |
| Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients | NCT04657315 | Glioblastoma Adult Gliosarco... Neoplasms, Brai... Neoplasms, Germ... Recurrent Gliob... | MSC11FCD | 19 Years - 70 Years | CHA University | |
| Multicenter Database of Patients With Germ Cell Tumor | NCT02863003 | Neoplasms, Germ... | 18 Years - | Latin American Cooperative Oncology Group | ||
| Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor | NCT02533765 | Neoplasms, Germ... | Olaparib | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases | NCT02859415 | Esophageal Neop... Lung Neoplasms Mesothelioma Thymus Neoplasm... Neoplasms, Germ... | Mithramycin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) | NCT00753415 | Non-Small Cell ... Breast Cancer Melanoma Upper GI Tract ... Colon Carcinoma Renal Cell Carc... Bladder Carcino... Prostate Cancer | V935 V934-EP | 18 Years - | Merck Sharp & Dohme LLC | |
| Vorasidenib Expanded Access Program | NCT05592743 | Glioma Recurrence Disease Attribu... Pathologic Proc... Neoplasms, Neur... Neuroectodermal... Neoplasms, Germ... Neoplasms by Hi... Neoplasms Neoplasms, Glan... Neoplasms, Nerv... | Vorasidenib | 12 Years - | Servier | |
| Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors | NCT01215578 | Neuroendocrine ... Pancreatic Neop... Advanced Diseas... Sunitinib | Sutent | 18 Years - | Assistance Publique - Hôpitaux de Paris |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
